UPDATED: Jennifer Doudna spinout inks a Mammoth CRISPR deal with Vertex worth nearly $700M
When a company gets its start in gene editing pioneer Jennifer Doudna’s lab, it’s bound to make headlines. But three years in, the fanfare still hasn’t died down for Mammoth Biosciences. Now, the Brisbane, CA-based company is cheering on its first major R&D pact.
Mammoth unveiled a nearly $700 million deal with Vertex on Tuesday morning, good for the development of in vivo gene therapies for two mystery diseases. The stars of the show are Mammoth’s ultra-small CRISPR systems, including two Cas enzymes licensed from Doudna’s lab over the past couple years, Cas14 and Casɸ.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.